



Universiteit
Leiden
The Netherlands

Pulmonary embolism : diagnostic management and prognosis

Klok, F.A.

Citation

Klok, F. A. (2010, March 2). *Pulmonary embolism : diagnostic management and prognosis*. Retrieved from <https://hdl.handle.net/1887/15031>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/15031>

Note: To cite this publication please use the final published version (if applicable).

PULMONARY EMBOLISM

Diagnostic management and prognosis

Frederikus A. Klok

© F.A. Klok, Leiden, The Netherlands. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanic, photocopying, and recording or otherwise, without prior written permission by the author.

ISBN 978-90-8559-917-3

Cover design: Marijn Ottenhof

Printed by Optima Grafische Communicatie, Rotterdam

PULMONARY EMBOLISM

Diagnostic management and prognosis

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op

dinsdag 2 maart 2010
klokke 16.15 uur

door

Frederikus Albertus Klok

geboren te Delft
in 1982

PROMOTIECOMMISSIE

Promotor

Prof. dr. J.A. Romijn

Co-Promotor

Dr. M.V. Huisman

Overige commissieleden

Prof. dr. F.W.G. Leebeek (Erasmus Medisch Centrum, Rotterdam)

Prof. dr. E.E. van der Wall

Prof. dr. A. de Roos

Prof. dr. J.H. Bolk

Dr. J.T. Tamsma

Dr. K.W. van Kralingen

Financial support by the Netherlands Heart Foundation and J.E. Jurriaanse Foundation for the publication of this thesis is gratefully acknowledged.

Additional financial support was provided by: Actelion Pharmaceuticals Nederland BV, Bayer BV, Boehringer-Ingelheim BV, GlaxoSmithKline, LEO Pharma BV, Merck Sharp & Dohme BV, Pfizer BV, Roche Diagnostics Nederland BV, Sanofi Aventis Nederland BV, Schering-Plough Nederland BV, Servier Nederland Farma BV, Toshiba medical systems Nederland, Federatie van Nederlandse Trombose Diensten, Stichting Beeldverwerking Leiden en Foundation Imago te Oegstgeest.

Contents

Chapter 1	Introduction	7
PART I DIAGNOSTIC MANAGEMENT OF ACUTE PULMONARY EMBOLISM		
Chapter 2	Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism	15
Chapter 3	Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism	23
Chapter 4	Safety of ruling out acute pulmonary embolism by normal CT pulmonary angiography in patients with an indication for CT: systematic review and meta-analysis	35
PART II SHORT TERM CLINICAL OUTCOME AFTER ACUTE PULMONARY EMBOLISM		
Chapter 5	Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: systematic review and meta-analysis	49
Chapter 6	Comparison of CT assessed right ventricular size and cardiac biomarkers for predicting short term clinical outcome in normotensive patients suspected for having acute pulmonary embolism	63
Chapter 7	Usefulness of ECG-synchronized MDCT assessed right and left ventricular function for predicting short term clinical outcome in patients with clinically suspected acute pulmonary embolism.	77
PART III LONG TERM CLINICAL COURSE OF ACUTE PULMONARY EMBOLISM		
Chapter 8	Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism	91
Chapter 9	A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism	103

Chapter 10	Prevalence and determinants of exertional dyspnea after acute pulmonary embolism	117
Chapter 11	Risk of arterial cardiovascular events in patients after pulmonary embolism	129
Chapter 12	Patient outcomes after acute pulmonary embolism: a pooled survival analysis of different adverse events	141
Chapter 13	Quality of life after pulmonary embolism: validation of the PEmb-QoL questionnaire	155
Chapter 14	General discussion and summary	167
Chapter 15	Nederlandse samenvatting	175
	List of publications	185
	Nawoord	189
	Curriculum Vitae	191